Introduction
It has all the elements of a medical thriller: a lifesaving drug, a Swiss pharma giant, a frustrated hospital CEO, and a regulatory body told to mind its own business. Instead, it is the premise of a landmark legal battle. In February 2026, the Supreme Court of India stepped into Competition Commission of India v. Swapan Dey and Anr. (Civil Appeal No. 519/2026), freezing the NCLAT's decision, holding that the Competition Act, 2002 is inapplicable wherever alleged anti-competitive conduct stems from the exercise of patent rights. This is now the most significant signal Indian competition law has received in years.
Background of the Dispute
Swapan Dey, the CEO of a hospital running dialysis services under the Pradhan Mantri National Dialysis Programme (PMNDP), filed a complaint before the CCI alleging anti-competitive conduct by Vifor International AG, a Swiss pharmaceutical company that held the patent for Ferric Carboxymaltose (FCM). FCM is an intravenous iron replacement therapy commonly required by dialysis patients who develop iron deficiency anaemia. His complaint invoked Section 3 and Section 4 of the Competition Act, 2002, alleging that Vifor's licensing arrangements with Indian manufacturers such as Emcure and Lupin imposed restrictive conditions, made the drug unaffordable, and amounted to both anti-competitive agreements and abuse of a dominant position.
The CCI closed the complaint on 25 October 2022, finding no prima facie violation. The closure order addressed the merits. What happened next was where the trouble began.
Appeal to the NCLAT
When Dey appealed to the NCLAT, the tribunal did not simply affirm the CCI's merits-based closure. It went further, holding that the CCI lacked jurisdiction altogether to examine allegations of anti-competitive conduct arising from the exercise of patent rights. The Patents Act, 1970, the tribunal said, is a specialised statute and a complete code. Competition law simply does not enter the picture.
To arrive at this conclusion, the NCLAT relied on Section 3(5)(i)(b) of the Competition Act, which provides that nothing in Section 3 shall restrict the right of any person to impose reasonable conditions in an agreement for protecting rights under the Patents Act. The tribunal read this provision as drawing a categorical line between patent rights and competition oversight.
The NCLAT also relied heavily on the Delhi High Court's Division Bench judgment of 13 July 2023 in Telefonaktiebolaget LM Ericsson (PUBL) v. CCI, which had reversed two earlier single-judge rulings and held that the Patents Act, as the later and more specific legislation, takes precedence over the Competition Act in patent-related matters. The Division Bench applied the maxims generalia specialibus non derogant (general things do not derogate from special things) and lex posterior derogat priori (a later law repeals an earlier law) to conclude that the CCI cannot exercise jurisdiction over the conduct of a patentee acting in exercise of patent rights. The NCLAT adopted that reasoning and arrived at a flat finding that jurisdiction is absent. The merits never mattered.
What the Supreme Court Did
On 2 February 2026, the Supreme Court agreed to take up the CCI's appeal, registered as Civil Appeal No. 519/2026. The bench of Justices JB Pardiwala and Vijay Bishnoi stayed those portions of the NCLAT order that removed CCI jurisdiction from the equation.
The Court was clear that it would decide only the jurisdictional question. The underlying dispute on the merits, whether Vifor's licensing arrangements actually violated the Competition Act, stays separate. Notice was issued to Swapan Dey and Vifor International AG.
By granting this stay, the Supreme Court kept alive the possibility that the CCI can, in fact, look into anti-competitive conduct tied to patent rights. The NCLAT's blanket jurisdictional exclusion does not operate for now.
The Legal Fault Line
The Patents Act, 1970 grants a patentee exclusive rights over the invention for a fixed term. Chapter XVI of the Patents Act addresses working of patents, compulsory licensing, and conditions on licensing. The Controller of Patents has powers under Section 84 to grant compulsory licences where a patentee abuses the monopoly. Patent holders and their advocates argue this makes the Patents Act a self-contained mechanism for addressing abusive patent practices.
The Competition Act, 2002 covers the other side. Section 4 prohibits abuse of dominant position. Section 62 provides that the Competition Act operates in addition to, and not in derogation of, other laws. Section 3(5) carves out protection for reasonable conditions imposed to protect IP rights, but the word "reasonable" does heavy lifting here. A condition designed to exclude competition from the market is a different matter entirely.
The practical difference between these two regimes is significant. The Controller of Patents addresses disputes between a patentee and a specific party, in personam. The CCI acts in rem, looking at the effect of conduct on the market as a whole. A compulsory licence granted by the Controller resolves one party's access to a drug. An order from the CCI on abuse of dominance addresses the pricing and licensing structure affecting the entire market.
The Supreme Court's earlier judgment in CCI v. Bharti Airtel, (2019) 2 SCC 521 had dealt with a similar jurisdictional overlap between the CCI and the Telecom Regulatory Authority of India (TRAI). The Court held that TRAI's fact-finding role does not oust CCI jurisdiction. The CCI's mandate begins after TRAI completes its domain-specific assessment. Curiously, the Delhi High Court's 2023 Division Bench in Ericsson did not explain why the Bharti Airtel reasoning would not apply equally in the patent context.
Why the Stay Matters Beyond This Case
The sectors watching this case most closely are pharmaceuticals and technology. Both rely on patent protections that can, in practice, translate into dominant market positions. When a patentee holds the exclusive right to manufacture or license a molecule, a technology standard, or a process, the gap between exclusivity and exclusion can be narrow.
Standard essential patents represent a particular flashpoint. As covered on this blog in the Bansal v. Philips SEP decree analysis, a holder of standard essential patents that refuses to license on fair, reasonable, and non-discriminatory terms is not merely exercising a patent right. That conduct has market-wide effects. The question of which forum addresses those effects, the Controller of Patents or the CCI, determines whether the remedy is an individual licence for one party or a systemic correction for the market.
A decision keeping CCI jurisdiction alive in patent-related abuse cases would reshape how pharmaceutical companies structure licensing arrangements, how tech companies negotiate SEP terms, and how dominant players in patented markets price their products. A decision that finally closes the door on CCI jurisdiction would, as multiple commentators have noted, risk making the Competition Commission progressively irrelevant in the very sectors where market distortion is most likely to arise.
The Vifor Factor
Vifor's patent over the FCM molecule expired on 21 October 2023, before the NCLAT even delivered its judgment on 30 October 2025. FCM passed into the public domain while the litigation was still alive.
Courts generally address questions of statutory importance even where the immediate facts have shifted, particularly when the issue is certain to recur. The FCM molecule expiring does not resolve the question of whether the CCI can investigate an active patent holder's pricing and licensing conduct. It just means this particular complaint may have no practical remedy at the end of the road. The jurisdictional question, however, remains very much alive for every patent dispute that comes after it.
The Broader Pattern
This is not the first time the courts have gone back and forth on this question. The Delhi High Court's single bench ruled in 2016 that the CCI can examine patent disputes. In 2020, it reaffirmed that view in the Monsanto matter. The Division Bench in 2023 reversed both. The NCLAT in October 2025 adopted the Division Bench position. The Supreme Court in February 2026 stepped in and stayed that position.
The inconsistency across tribunals and courts over a decade reflects the absence of a clear legislative answer. Parliament built both regimes but did not explicitly resolve the conflict between them. Section 62 of the Competition Act says it supplements other laws. Section 3(5) says it protects reasonable IP conditions. Neither provision answers the specific question of whether a pattern of anti-competitive conduct, wrapped in a patent licence, falls under the CCI's mandate.
This question of exclusivity crossing into exclusion appears across IP categories, as covered in the trademark infringement and deceptive similarity analysis on this blog. The legal regime governing where that line falls differs across trademark, copyright, and patent law. In patents, as this case makes clear, the question of who draws that line remains unanswered.
The patent application rejection case exploring principles of natural justice, covered earlier on this blog, also signals how procedural and jurisdictional clarity in patent law carries consequences far beyond the individual dispute. A system where the wrong forum handles a complaint is a system that delivers no remedy at all.
Conclusion
The Supreme Court's stay in CCI v. Swapan Dey is a signal that the NCLAT's categorical exclusion of CCI jurisdiction over patent-related conduct is not the last word. A Supreme Court bench found sufficient reason to pause that exclusion while it examines the question properly. My reading of the direction this case is headed is this. The Supreme Court will reject the maximalist position that the Patents Act is a complete code immunising all patent-related conduct from competition scrutiny. That reading rests on what Section 62 of the Competition Act says plainly, competition law supplements other legislation, not the reverse. It also rests on the structural reality that the Controller of Patents and the CCI serve different functions. Individual licensing disputes belong before the Controller. Market-wide anti-competitive effects, where the dominant position created by a patent is wielded to exclude rather than to protect, belong before the CCI.
Stripping the CCI of jurisdiction wherever a patent is involved would create a straightforward playbook for dominant players in pharma, tech, and agriculture to conduct business outside antitrust oversight, simply by structuring conduct through licensing agreements. That outcome is difficult to reconcile with the purpose of the Competition Act. The final judgment will be one of the more consequential IP decisions this decade. This one is worth watching closely.
Disclaimer: None of the contents of this post constitute legal advice.